Nuclear Export Inhibitor, Selinexor+Bortezomib+Dexamethasone (SVd), 1,2,3 prior line of therapy, Phase 3, Relapsed Refractory Multiple Myeloma (RRMM), Bortezomib+Dexamethasone (Vd)
### Instruction:
Identify the study with the following condition. 
### Input:
Nuclear Export Inhibitor, Selinexor+Bortezomib+Dexamethasone (SVd), 1,2,3 prior line of therapy, Phase 3, Relapsed Refractory Multiple Myeloma (RRMM), Bortezomib+Dexamethasone (Vd) 
### Output:
Popular Name is BOSTON, Study ID is NCT03110562